

09/888,840

13780-2/226A/CO93.US CP2

**REMARKS****AMENDMENTS TO THE SPECIFICATION**

The specification has been amended in the interest of clarity and to correct typographical and grammatical errors. These amendments do not add new matter as detailed below. Entry of these amendments is respectfully requested.

**Specification Amendments Beginning on Page 4, Line 8, and Ending on Page 6, Line 14.**

The phrase "compounds of the structure" has been removed and replaced with "compounds of Formula I" for clarity. This sentence now clearly refers to the labeled Formula I below.

The phrase "or a pharmaceutically-acceptable salt, optical isomer or prodrug thereof," has been moved from the end of the definitions for the compounds of Formula I to the beginning of the definitions for clarity. This phrase has also been amended to correct a grammatical error. The phrase now refers to the plural form of the noun, stating "or pharmaceutically-acceptable salts, optical isomers or prodrugs thereof."

The definition for  $R^1-R^5$  has been amended to clarify the definition for the group of Formula II. The proviso that one of  $R^1$  or  $R^3$  must be selected from a group of Formula II has been placed below this formula in the claim.

The definition of  $R^{10}$  and  $R^{11}$  for the compounds of Formula I has been amended for clarity. In particular, the expressions "may be joined" and "said ring being optionally substituted" have been amended and the terms "unsubstituted" and "substituted" have been added to clarify that the heterocycle ring is unsubstituted or substituted. The definition of  $R^{10}$  and  $R^{11}$  now states ". . .  $R^{10}$  and  $R^{11}$  are taken together with N to form a three to seven membered unsubstituted heterocyclyl ring, or a three to seven membered substituted heterocyclyl ring, substituted with one or more than one substituent  $R^{13}$ , . . ."

09/888,840

13780-2/226A/CO93.US CP2

The definition of A has been amended to clarify that the aryl and heterocyclic groups can be either unsubstituted or substituted. The phrase "hydrogen" has accordingly been deleted from the list of substituents for R<sup>12</sup>.

These amendments are made for clarity and/or to correct typographical errors and do not add new matter.

**Specification Amendments Beginning on Page 6, Line 18, and Ending on Page 8, Line 16.**

The phrase "compounds of the structure" on page 6, line 18 has been removed and replaced with "compounds of Formula III" for clarity. This sentence now clearly refers to the labeled Formula III below.

The phrase "D, B, Y, and Z are as defined above" on page 7, line 5 has been amended to recite "D, B, Y, and Z are as defined above for Formula I," to clarify that this phrase refers to Formula I.

The R<sup>12</sup> definitions on pages 7 and 8 for Formulas III and IV, respectively, have been amended to delete the hydrogen substituent for consistency with the amendments to the R<sup>12</sup> definition for Formula I, as described above.

The R<sup>10</sup> and R<sup>11</sup> definitions on pages 7 and 8 have been amended as described above for the amendments to the definitions for Formula I.

The phrase "compounds of the structure" on page 7, line 18 has been removed and replaced with "compounds of Formula III" for clarity. This sentence now clearly refers to the labeled Formula IV below.

These amendments are made for clarity and/or to correct typographical errors and do not add new matter.

**Specification Amendments Beginning on Page 28, Line 10, and Ending on Page 31, Line 10.**

09/888,840

13780-2/226A/CO93.US.CP2

The specification, page 28, lines 10-14, has been amended slightly in the interest of clarity. In particular, the term "ring" has been added to line 10, to refer to the oxazole ring shown in Scheme 1. The sentence "In Scheme 1, and likewise in Schemes 2 and 4, the substituent X is a leaving group" has been added. The new sentence describes Schemes 1, 2, and 4 which all contain aryl methyl ketone 1. The terms (R<sub>1-2</sub>, and R<sub>4-5</sub>) have been added to describe the substitution as seen on aryl methyl ketone 1 in Scheme 1 (amended as described below). The number 2 has been added after the term "Biarylsulfide," to refer to the biarylsulfide shown in Scheme 1. The term "oxazole" has been added to line 14 in reference to compound 4, shown in Scheme 1, as an oxazole compound. The above-described amendments merely clarify the invention as described in the specification and shown in Schemes 1, 2, and 4 and no new matter is added by these amendments.

The description of Schemes 1-6, on pages 28-31 of the specification has also been amended to correct obvious typographical and/or grammatical errors. In particular, the plural form for referencing a compound structure has been changed to the singular form, when a single compound structure is described. The above amendments merely correct typographical and/or grammatical errors and clarify the invention as described in the specification and shown in Schemes 1-6.

Schemes 1-6 have been amended to correct obvious typographical errors in the interest of clarity. Specifically, the R<sub>1-4</sub> group in these schemes is now represented by two groups, R<sup>1-2</sup>, and R<sup>4-5</sup>, and the Ar group lettering has been changed to A. The R group numbering and A group lettering is now consistent with the numbering and lettering shown in Formula I, on page 4, line 9 of the Specification, and in Claim 1, p. 121, line 4. Schemes 1-6 have also been amended such that the numbering of NR<sub>9</sub>R<sub>10</sub> is changed to NR<sup>10</sup>R<sup>11</sup>. This R group numbering is now consistent with the numbering shown in Formula II, on page 4, line 14 of the Specification, and in Claim 1, p. 121, line 10. Scheme 6 has further been amended such that Compound 22 is consistent with the remainder of Scheme 6. Specifically, the CH<sub>3</sub> group in Compound 22 has been changed to R<sup>1-2</sup> and R<sup>4-5</sup> groups. Compound 22, as amended,